The purpose of this study is to evaluate the safety and efficacy of autologous peripheral hematopoietic stem cell transplantation in ischemic stroke.
Stroke is among the main causes of mortality and disability of elderly population which still lack of efficient therapy. Stem sell transplantation provides a functional improvement after cerebral ischemia in rat models. Our study will recruit 40 ischemic stroke patients which will be divided into 2 groups (20 patients each): treatment group and control group. The former will be implanted with peripheral blood stem cell through anterior cerebral artery or middle cerebral artery (determined by the section of infarction) and receive convention stroke therapy. The latter only receive convention stroke therapy. The investigators expect that transplantation of the peripheral hematopoietic stem cell is safe and efficient to neurological recovery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Yaguo Li
Hangzhou, Zhejiang, China
RECRUITINGChange from Baseline in NIH-stroke scale (NIHSS) at 12 months
Time frame: 1,3,6,12 months after cell transplantation
Barthel index
Time frame: 1,3,6,12 months after cell transplantation
perfusion magnetic resonance imaging scan
Time frame: 1,3,6,12 months after cell transplantation
Modified Rankin Scale(mRS)
Time frame: 3,6,12 months after cell transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
atorvastatin 20mg,qd,po
edaravone 30mg,bid,ivgtt.
aspirin 100mg,qd,po(patients with no fibrillation atrial)
warfarin 2\~6mg,qd,po(patients with fibrillation atrial)
atorvastatin 20mg,qd,po
edaravone 30mg,bid,ivgtt